Acorda Therapeutics, Inc. operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Acorda Therapeutics with three other
companies in this sector in the United States:
Neurocrine Biosciences Inc
sales of $451.24 million
of which 100%
of which 61%
was SCIT/SLIT drops), and
of which 66%
During the year ended December of 2018, sales at
Acorda Therapeutics were $471.43 million.
decrease of 19.9%
versus 2017, when the company's sales were $588.29 million.